T-Bird Subsidiary Signs Lease Agreement for Second Facility

T-Bird Pharma Inc. (TSXV:TPI) announced that it subsidiary, Thunderbird Biomedical Inc., has signed a definitive lease agreement for a second facility. It will be located in Victoria, British Columbia.

As quoted in the press release:

The facility has 28,966 square feet of floor space with the option to add approximately 14,500 square feet of mezzanine space for a total of approximately 43,500 square feet.

Architectural and engineering work has started and the Company expects infrastructure work to commence in October. Based on the time required for municipal permitting and construction, Thunderbird aims to have the first Health Canada inspection of the new facility in Q1-2015.

Rob Gagnon, CEO of T-Bird, commented:

After fine tuning our pharmaceutical-grade manufacturing processes at our current facility (3,100 square feet) we are excited to be executing on the first phase of a multi-phase expansion of our business.  We look forward to demonstrating the scalability of our platform while ensuring a consistent premium quality product for the Canadian market.

Click here to read the full T-Bird Pharma Inc. (TSXV:TPI) press release.